RxDoctor Payments Data

Michael D'angelo, MD

Urology · Ocoee, FLNPI 1114969235

Payments from drug & device makers

$120,414in general payments, 2019–2025

Across 420 payments — averaging $286.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$106K
  • Arrow International, Inc.$5K
  • Neotract Inc.$2K
  • Boston Scientific$809
  • Pfizer$460
  • AbbVie$449
  • plus $6K from 42 others
$5,730in research payments, 2019–2025

Across 1 payment — averaging $5730.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Celltrion, Inc.$6K

What the payments were for

  • Consulting fees$7,1386%
  • Speaking & faculty fees$97,68481%
  • Travel & lodging$2,4352%
  • Food & beverage$12,69411%
  • Education$4640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$120,414 in reported general payments places this provider in the 90th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$195,624
Medicare patients
389
Services billed
2,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide23$326,127
OrgovyxRelugolix26$65,546
GemtesaVibegron62$55,825
MyrbetriqMirabegron81$50,645
Silodosin111$8,977
Tamsulosin Hcl365$5,094
Estradiol60$4,013
Solifenacin Succinate74$2,987
Testosterone29$2,121
Finasteride130$1,711
Tadalafil50$1,206
Testosterone Cypionate30$775
Alfuzosin Hcl ErAlfuzosin Hcl35$686
Sildenafil Citrate56$655
NitrofurantoinNitrofurantoin Macrocrystal26$583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$435$326,12723 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$170$121,37188 claims
Astellas Pharma US IncMyrbetriq$273$50,64581 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 urology providers in Florida.

Other urology in Ocoee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →